ArticleAmerican journal of translational research2026
Shengjiang San modification promotes colonic mucosal repair in ulcerative colitis rats by inhibiting lauric acid-Shigella synergistic damage via PKC signaling pathway.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesUlcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease. Recent research has focused on microbial dysbiosis within the gut environment. Although Shengjiang San modification ameliorates inflammation via activation of the PKC signaling pathway, the specific molecular mechanisms underlying its anti-inflammatory effects remain unclear. This study aimed to systematically investigate the anti-inflammatory mechanisms of Shengjiang San modification.
methodsUC models were established in 50 male SD rats using Dextran Sulfate Sodium Salt (DSS). Rats were divided into model group, mesalazine group, and Shengjiang San modification high/mid/low-dose groups. After 14 days of intervention, samples were collected. General condition, gross colon morphology, and histopathological changes were observed. Untargeted metabolomics was used to detect serum metabolites, 16S rRNA sequencing was performed to analyze gut microbiota, and combined multi-omics analysis was conducted.
resultsShengjiang San modification significantly improved colonic pathological injury and restored body weight. Metabolomics identified 18 aberrant metabolites, with 16 returning to near-normal levels after treatment, primarily involving the protein kinase C (PKC) signaling pathway. Gut microbiota analysis revealed decreased pathogenic bacteria and significantly increased beneficial bacteria. Notably, the lauric acid-Shigella correlation was disrupted. Compared to the control group, the high-dose group showed superior efficacy in restoring the Firmicutes/Bacteroidetes (F/B) ratio.
conclusionsShengjiang San modification exerts anti-inflammatory effects and promotes colonic mucosal repair in UC rats by blocking lauric acid-Shigella synergistic damage via the PKC signaling pathway. The high-dose formulation demonstrated optimal therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.